DS-AD

Health and Research – Alzheimer's/Dementia Resources for Professionals

Alzheimer’s Disease in People with Down Syndrome: What We Know and What We Can Do About It

In this webinar, Dr. Michael Rafii joins the National Down Syndrome Society (NDSS) to discuss…

Kim WarrenMarch 6, 2024

Health and Research – Alzheimer's/Dementia

Facts About Dementia

Fact sheet about dementia and intellectual disabilities from the NTG.Source: National Task Group on Intellectual…

Kim WarrenFebruary 6, 2024

Resources for Professionals

Modeling the Impact of Research Investment on Down Syndrome–Associated Alzheimer’s Disease

Individuals with Down syndrome (DS) are living longer than they used to. This trend has…

Kim WarrenJanuary 19, 2024

General DS Information

myDSC Newsletter – January 2023

This edition of the newsletter includes self-care tips, upcoming webinars and more.I hope you all…

Capetivate capetivateJanuary 12, 2023

Resources for Professionals

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study

With improved healthcare, the Down syndrome (DS) population is both growing and aging rapidly. However,…

Rigsby RigsbyMay 3, 2022

Health and Research – Alzheimer's/Dementia

Why Patient Voices Are So Critical to the Development and Initial Approval of New Drugs

This blogpost from a former FDA insider on the power of the patient helps us…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

Biogen Announces New Hope for Alzheimer’s Drug Candidate Aducanumab

On October 22, 2019, the biopharmaceutical company, Biogen, announced that they will be going to…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

LuMind IDSC signs on to NTG statement re: Aduhelm

“It is unknown to what degree aducanumab (Aduhelm) may help people with Down syndrome, as…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage

LuMind IDSC has joined the National Down Syndrome Society (NDSS) and The National Task Group…

Rigsby RigsbyOctober 27, 2021

Health and Research – Alzheimer's/Dementia

FDA Approves Biogen’s Aduhelm, the First New Drug for Alzheimer’s Disease Since 2003

Today marks an important milestone in Alzheimer’s disease research with the approval by the FDA…

Rigsby RigsbyOctober 27, 2021

Facts About Dementia

Modeling the Impact of Research Investment on Down Syndrome–Associated Alzheimer’s Disease

myDSC Newsletter – January 2023

Cross-Sectional Exploration of Plasma Biomarkers of Alzheimer’s Disease in Down Syndrome: Early Data from the Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study

Why Patient Voices Are So Critical to the Development and Initial Approval of New Drugs

Biogen Announces New Hope for Alzheimer’s Drug Candidate Aducanumab

LuMind IDSC signs on to NTG statement re: Aduhelm

LuMind IDSC and Other National Groups Urge CMS to Include DS Community in Alzheimer’s Drugs Coverage

FDA Approves Biogen’s Aduhelm, the First New Drug for Alzheimer’s Disease Since 2003

CONTACT LUMIND IDSC

QUICK LINKS

JOIN US